Added value of end of life and orphan medicines: a thematic analysis from the patient/carer perspective

Jan Jones, Eileen Harkess-Murphy, Lindsay Lockhart, Anne Lee, Jonathan Fox, Ailsa Brown (Contributor)

Research output: Contribution to conferencePoster

Abstract

The Scottish Medicines Consortium advises NHS Scotland on the clinical and cost-effectiveness of new medicines. Recent process changes have given patients and clinicians a stronger voice in decisions for end of life and orphan medicines. Thematic analysis of information provided by patients and carers has improved our understanding of the key factors that are important to patients.
Original languageEnglish
Publication statusPublished - 10 May 2016
Externally publishedYes
EventHTAi 2016 Annual Meeting : Informing Health Care Decisions with Values and Evidence - Keio Plaza Hotel, Tokyo, Japan
Duration: 10 May 201614 May 2016
http://meeting.htai.org/events/tokyo2016/event-summary-4023afce0ec04ab387500e87f0a6a42d.aspx (Conference website)

Conference

ConferenceHTAi 2016 Annual Meeting
Abbreviated titleHTAi 2016
Country/TerritoryJapan
CityTokyo
Period10/05/1614/05/16
Internet address

Fingerprint

Dive into the research topics of 'Added value of end of life and orphan medicines: a thematic analysis from the patient/carer perspective'. Together they form a unique fingerprint.

Cite this